The MarketWatch News Department was not involved in the creation of this content. -- Potential first-in-class, and industry-leading DNA polymerase Theta (Pol ) inhibitor, ART6043 demonstrated an ...
Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar. We'll be talking in depth today with some of our Lantern's team and also with our collaborator and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results